Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: A retrospective registry analysis on 698 patients by the chronic malignancies working party of the european society of blood and marrow transplantation

Christoph Schmid*, Liesbeth C. De Wreede, Anja Van Biezen, Jürgen Finke, Gerhard Ehninger, Arnold Ganser, Liisa Volin, Dietger Niederwieser, Dietrich Beelen, Paolo Alessandrino, Lothar Kanz, Michael Schleuning, Jakob Passweg, Hendrik Veelken, Johan Maertens, Jan J. Cornelissen, Didier Blaise, Martin Gramatzki, Noel Milpied, Ibrahim Yakoub-AghaGhulam Mufti, Montserrat Rovira, Renate Arnold, Theo De Witte, Marie Robin, Nikolaus Kröger

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    75 Citations (Scopus)

    Abstract

    No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. We performed a retrospective registry analysis of outcomes and risk factors in 698 patients, treated with different strategies. The median overall survival from relapse was 4.7 months (95% confidence interval: 4.1-5.3) and the 2-year survival rate was 17.7% (95% confidence interval: 14.8-21.2%). Shorter remission after transplantation (P<0.001), advanced disease (P=0.001), older age (P=0.007), unrelated donor (P=0.008) and acute graft-versus-host disease before relapse (P<0.001) adversely influenced survival. At 6 months from relapse, patients had received no cellular treatment, (i.e. palliative chemotherapy or best supportive care, n=375), donor lymphocyte infusion (n=213), or a second transplant (n=110). Treatment groups were analyzed separately because of imbalanced characteristics and difficulties in retrospectively evaluating the reason for individual treatments. Of the patients who did not receive any cellular therapy, 109 were alive at 6 months after relapse, achieving a medianoverall survival from this landmark of 8.9 months (95% confidence interval: 5.1-12.6). Their 2-year survival rate was 29.7%. Recipients of donor lymphocytes achieved a median survival from first infusion of 6.0 months (95% confidence interval: 3.7-8.3) with a 2-year survival rate of 27.6%. Longer remission after first transplantation (P<0.001) and younger age (P=0.009) predicted better outcome. Among recipients of a second transplant, the median survival from second transplantation was 4.2 months (95% confidence interval: 2.5-5.9), and their 2-year survival rate was 17.0%. Longer remission after first transplantation (P<0.001), complete remission at second transplant (P=0.008), no prior chronic graft-versus-host disease (P<0.001) and change to a new donor (P=0.04) predicted better outcome. The data enabled identification of patients benefiting from donor lymphocyte infusion and second transplantation, and may serve as a baseline for prospective trials.

    Original languageEnglish
    Pages (from-to)237-245
    Number of pages9
    JournalHaematologica
    Volume103
    Issue number2
    DOIs
    Publication statusPublished - 31 Jan 2018

    Fingerprint

    Dive into the research topics of 'Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: A retrospective registry analysis on 698 patients by the chronic malignancies working party of the european society of blood and marrow transplantation'. Together they form a unique fingerprint.

    Cite this